news
EMA begins rolling review of Novavax’s NVX-CoV2373 COVID-19 vaccine
The review will evaluate data from preclinical and clinical studies of NVX-CoV2373 to expedite the vaccine’s marketing authorisation approval later.
List view / Grid view
Vaccines
news
Investigational COVID-19 vaccine tablet safely induces immune response in Phase I
A preliminary analysis shows VXA-CoV2-1 was well-tolerated and induced T-cell and IgA responses against SARS-CoV-2 antigens in 35 patients.
news
Intranasal influenza vaccine produces strong immune response, Phase I study shows
A Phase I clinical trial has shown that Ad4-H5-VTN, a single-dose, intranasal influenza vaccine, was safe and produced an immune response.
news
UK launches trial to study alternating COVID-19 vaccines for different doses
The UK Government has given £7 million of funding for a clinical trial which will investigate whether patients can be given different COVID-19 vaccines for each dose.
article
Is intranasal drug delivery the best way to administer COVID-19 therapeutics?
In this article, we investigate three of the latest developments in COVID-19 therapeutics that are delivered intranasally.
whitepaper
Brochure: G-CON cleanroom POD
G-CON cleanroom PODs. Reliable, flexible prefabricated cleanrooms for the biopharmaceutical industry. On budget and on time.
news
2020 – the best year for UK biotech investments ever recorded, says BIA
Report finds 2020 was a record-breaking year for investment in UK biotech, driven by innovation and the COVID-19 pandemic, with growth anticipated to continue into 2021.
![syringe drawing from a vial labelled AstraZeneca COVID-19 Vaccine [Credit: Juan Roballo / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_1863086803-300x278.jpg)
![syringe drawing from a vial labelled AstraZeneca COVID-19 Vaccine [Credit: Juan Roballo / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_1863086803.jpg)
news
AstraZeneca’s COVID-19 vaccine prevents severe disease and hospitalisation in Phase III trials
A preliminary analysis suggests the COVID-19 Vaccine AstraZeneca was 74 percent effective after the first dose and 82 percent effective with a 12-week inter-dose interval.
news
Phase III trial shows Sputnik V COVID-19 vaccine is 91.6 percent effective
An interim analysis from a Phase III trial of the Sputnik V vaccine has shown it is effective against symptomatic COVID-19.
news
COVID-19 vaccine shows promise against UK’s new variant
Novavax’s NVX-CoV2373 vaccine candidate was 89.3 percent effective overall and 85.6 percent effective against the B.1.1.7 SARS-CoV-2 variant, in a Phase III trial.
news
J&J COVID-19 vaccine shows success in interim analysis of Phase III trial
An interim analysis has shown that the COVID-19 vaccine developed by J&J is safe and effective at preventing the coronavirus in adults.
news
EMA committee recommends 13 medicines for approval in January meeting
The committee for human medicinal products recommended AstraZeneca’s COVID-19 vaccine be granted conditional marketing authorisation alongside 12 other approvals.
news
AstraZeneca to provide EU with extra nine million doses of COVID-19 vaccine following dispute
After manufacturing delays, AstraZeneca will now provide the EU with the 40 million COVID-19 vaccine doses it originally agreed to supply.
news
UK Government orders 100 million doses of Valneva COVID-19 vaccine
The UK Government has ordered a further 40 million doses of Valneva’s COVID-19 vaccine candidate, to be manufactured in Scotland.
news
CEPI offers $140 million to support research on COVID-19 vaccines
CEPI has opened a new funding opportunity, providing up to $140 million to support additional clinical research on COVID-19 vaccines.
